11/F, AXA Centre, 151 Gloucester Road
59 articles with Ascentage Pharma
Ascentage Pharma and MD Anderson Cancer Center Announce Strategic Alliance in Cancer Drug Development
Five-year collaboration aims to accelerate clinical development of select novel apoptosis-targeted and tyrosine kinase inhibitor product candidates
Collaboration to evaluate combination of APG-115, Ascentage's MDM2-p53 inhibitor and genolimzumab, Genor's anti-PD-1 monoclonal antibody in solid tumors and blood cancers
Ascentage Pharma Announces Oral Presentation of Novel, Third-Generation BCR-ABL Inhibitor in Myelogenous Leukemia Patients at the 60th American Society of Hematology Annual Meeting
Ascentage Pharma today announced data from a Phase 1 clinical study of its novel BCR-ABL inhibitor, HQP1351, in patients with Tyrosine Kinase Inhibitor (TKI)-refractory chronic myelogenous leukemia (CML) at the 60th American Society of Hematology (ASH) Annual Meeting.
Ascentage Pharma announced today that the Company will present clinical data of its novel BCR-ABL inhibitor HQP1351 in the upcoming 60th Annual Meeting of the American Society of Hematology (ASH)
Ascentage Pharma Presenting New Clinical Data of Novel Dual Bcl-2/Bcl-xL Inhibitor APG-1252 at Asia Conference on Lung Cancer 2018 (ACLC)
Ascentage Pharma Group Corporation, Ltd. announced today that the company presented the new clinical data of the dual Bcl-2/Bcl-xL inhibitor APG-1252.
Funding to support broad and innovative product pipeline of apoptosis-targeted candidates and build-out of state-of-the-art R&D centers and manufacturing facilities
One month after sharing promising interim-Phase I data at the American Society of Clinical Oncology, China-based Ascentage Pharma secured $150 million in Series C financing that will be used to support the development of its pipeline.
Ascentage Pharma Announces Promising Phase 1 Interim Results in Two Clinical Programs to Be Presented at 2018 ASCO Annual Meeting
Ascentage Pharma, a global clinical-stage biopharmaceutical company dedicated to developing apoptosis-targeted therapies for cancers and other diseases, today announced that interim results from two clinical programs will be presented at the 2018 American Society of Clinical Oncology (ASCO) annual meeting in Chicago, June 1-5, 2018.
Ascentage Pharma Announces Five Abstracts To Be Presented at the 2018 American Association for Cancer Research Annual Meeting
Ascentage Pharma announced that research on its pipeline of small molecule therapeutics will be presented at the 2018 American Association for Cancer Research (AACR) annual meeting in Chicago, April 14-18, 2018.
Ascentage Pharma Announces Acceptance of IND Application by China FDA for Clinical Study of Novel IAP Inhibitor to Treat Hepatitis B Infection
APG-1387 is the first IAP inhibitor to be studied in patients with HBV in China.
The newly formed board will be chaired by the former CEO of the ASCO, Dr. Allen Lichter, who is joined by Dr. Shaomeng Wang, Ascentage's Co-founder and CSO, and the Warner-Lambert/Parke-Davis Professor in Medicine at the University of Michigan, among other internationally recognized clinical oncology researchers and specialists.
Ascentage Pharma Announces U.S. FDA Acceptance of IND Application for Clinical Study of Novel IAP Inhibitor APG-1387 to Treat Advanced Solid Tumors and Blood Cancers
The Company believes that this dual inhibition may improve its effectiveness for more cancers.
Yingjie (Jason) Huang, M.D., To Join Ascentage Pharma As Senior Vice President Of Clinical Development
Ascentage Pharma Announces Series B Financing of RMB 500 Million To Advance Its Apoptosis-Targeted Novel Therapeutics
Ascentage Pharma And Unity Biotechnology Announce Collaboration For The Development Of Senolytic Healthspan Therapies